Passage Bio
PASG
75 hedge funds and large institutions have $38.1M invested in Passage Bio in 2022 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 31 reducing their positions, and 19 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.27% less ownership
Funds ownership: 3.88% → 3.62% (-0.27%)
12% less funds holding
Funds holding: 85 → 75 (-10)
51% less capital invested
Capital invested by funds: $78.4M → $38.1M (-$40.3M)
52% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 31
53% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 19
Top Buyers
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$4.59M |
| 2 |
Renaissance Technologies
New York
|
+$465K |
| 3 |
Millennium Management
New York
|
+$380K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$342K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$321K |
Top Sellers
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$2.69M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$2.47M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$1.74M |
| 4 |
Morgan Stanley
New York
|
-$1.08M |
| 5 |
NM
Newtyn Management
New York
|
-$631K |
PASG Hedge Fund Activity: Q3 2022 in Review
75 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q3 2022, worth a combined $38.1M — down 51% from $78.4M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of PASG and 9 opened new positions — a net loss of 10 holders — while 31 trimmed existing stakes and 15 added.
The largest buyer was Lynx1 Capital Management, adding an estimated $4.59M. The largest seller was Woodline Partners, cutting an estimated $2.69M.
- 75 institutional investors held Passage Bio (PASG) as of Q3 2022, down from 85 in Q2 2022.
- Funds reported $38.1M of Passage Bio stock for Q3 2022, down 51% quarter-over-quarter.
- 9 funds opened new Passage Bio positions in Q3 2022 and 19 closed out, a net change of -10 holders.
- The largest Passage Bio buyer in Q3 2022 was Lynx1 Capital Management, an estimated $4.59M added.
- The largest Passage Bio seller in Q3 2022 was Woodline Partners, an estimated $2.69M sold.
Based on aggregated 13F filings for Q3 2022.